Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eviplera vs Atripla on Lipid Profile in HIV-1 Patients
NCT02547844Phase 4Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Sep 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Changes in plasma lipid profile measured by lipidomic at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02547844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547844.